DK2004676T3 - Peptider af regulatoriske eller accessoriske proteiner af hiv, sammensætninger og anvendelse deraf - Google Patents

Peptider af regulatoriske eller accessoriske proteiner af hiv, sammensætninger og anvendelse deraf Download PDF

Info

Publication number
DK2004676T3
DK2004676T3 DK07705325.4T DK07705325T DK2004676T3 DK 2004676 T3 DK2004676 T3 DK 2004676T3 DK 07705325 T DK07705325 T DK 07705325T DK 2004676 T3 DK2004676 T3 DK 2004676T3
Authority
DK
Denmark
Prior art keywords
9hivl
emb
polypeptide
dbj
seq
Prior art date
Application number
DK07705325.4T
Other languages
English (en)
Inventor
Gregory Alan Stoloff
Wilson Romero Caparrã¿S-Wanderley
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0604920A external-priority patent/GB0604920D0/en
Priority claimed from GB0614260A external-priority patent/GB0614260D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Application granted granted Critical
Publication of DK2004676T3 publication Critical patent/DK2004676T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (18)

1. Polypeptid bestående af fra 30-45 aminosyrer, hvilket polypeptid omfatter SEQ ID NO: 1 eller en sekvens med mindst 85 % homologi med SEQ ID NO: 1: SEQ ID NO: 1 GDTWAGVEAIIRILQQLLFIHFRIGCQHSR hvor polypeptidet er immunogent for en HIV-stamme hos et hvirveldyr, der udtrykker et større histokompatibilitetskompleks- (MHC) allel.
2. Polypeptid ifølge krav 1, hvilket polypeptid omfatter en cytotoksisk T-lymfocyt (CTL), CD8+ T-celle- og/eller CD4+ T-celleepitop.
3. Polypeptid ifølge et hvilket som helst af de foregående krav, hvor homologien i alt væsentligt er 100 %.
4. Immunogent multi-epitoppolypeptid omfattende to eller flere polypeptider som defineret i et hvilket som helst af de foregående krav.
5. Polypeptidsanmiensætning, der omfatter to eller flere polypeptider, der er immunogene for en HIV-stamme hos et hvirveldyr, hvor ét af de to eller flere polypeptider er som defineret i et hvilket som helst af de foregående krav.
6. Polypeptidsammensætning ifølge krav 5, der endvidere omfattet ét eller flere polypeptider, der ikke har flere end 50 aminosyrer, hvor hvert polypeptid omfatter én eller flere sekvenser med 85 % eller større homologi med en hvilken som helst af SEQ ID NO: 2, SEQ ID NO: 3 eller SEQ ID NO: 4.
7. Polypeptidsammensætning ifølge krav 6, hvori sammensætningen omfatter et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 1 eller en sekvens med 85 % eller større homologi med SEQ ID NO: 1; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 2 eller en sekvens med 85 % eller større homologi med SEQ ID NO: 2; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 3 eller en sekvens med 85 % eller større homologi med SEQ ID NO: 3; og et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 4 eller en sekvens med 85 % eller større homologi med SEQ ID NO: 4.
8. Polypeptidsammensætning ifølge krav 7, hvori sammensætningen omfatter et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 1 eller en sekvens med 95 % eller større homologi med SEQ ID NO: 1; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 2 eller en sekvens med 95 % eller større homologi med SEQ ID NO: 2; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 3 eller en sekvens med 95 % eller større homologi med SEQ ID NO: 3; og et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 4 eller en sekvens med 95 % eller større homologi med SEQ ID NO: 4.
9. Polypeptidsammensætning ifølge krav 8, hvori sammensætningen omfatter et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 1; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 2; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 3; og et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 4.
10. Polypeptid ifølge krav 1-4 eller polypeptidsammensætning ifølge krav 5-9, der er immunogen for en flerhed af HIV-stammer.
11. Polypeptid ifølge krav 1-4, eller polypeptidsammensætning som defineret i krav 5-10 til anvendelse i medicin.
12. Fremgangsmåde til fremstilling af et polypeptid som defineret i krav 1-4, hvilken fremgangsmåde omfatter kombinering af to eller flere epitoper for at danne polypeptidet.
13. Polypeptidkonstrukt, hvilket konstrukt omfatter et polypeptid som defineret i krav 1-4 og en bærer.
14. Fremgangsmåde til fremstilling af et polypeptidkonstrukt som defineret i krav 13, hvilken fremgangsmåde omfatter kombinering af polypeptidet med bæreren.
15. Polypeptidkonstrukt eller fremgangsmåde ifølge krav 13 eller krav 14, hvor bæreren er et molekyle, og fortrinsvis hvor bæreren omfatter et adjuvans og/eller en excipiens.
16. Medikament eller vaccinesammensætning til anvendelse i behandling eller forebyggelse af en HIV-virusinfektion, omfattende et polypeptid ifølge krav 1-4, en polypeptidsammensætning ifølge krav 5-10, eller et polypeptidkonstrukt ifølge krav 13 og 15 og eventuelt en egnet excipiens og/eller adjuvans.
17. Fremgangsmåde til fremstilling af et medikament eller en vaccinesammensætning som defineret i krav 16, hvilken fremgangsmåde omfatter blanding af et polypeptid som defineret i et hvilket som helst af kravene 1-4 med en egnet excipiens og/eller adjuvans.
18. Polypeptid ifølge krav 1-4, polypeptidsammensætning ifølge krav 5-10 eller polypeptidkonstrukt ifølge krav 13 eller 15 til anvendelse i behandling eller forebyggelse af en HIV-virusinfektion.
DK07705325.4T 2006-03-10 2007-03-09 Peptider af regulatoriske eller accessoriske proteiner af hiv, sammensætninger og anvendelse deraf DK2004676T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0604920A GB0604920D0 (en) 2006-03-10 2006-03-10 Peptide sequences and compositions
GB0614260A GB0614260D0 (en) 2006-07-18 2006-07-18 Peptide sequences and compositions
PCT/GB2007/000812 WO2007104932A2 (en) 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof

Publications (1)

Publication Number Publication Date
DK2004676T3 true DK2004676T3 (da) 2017-02-20

Family

ID=38232608

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07705325.4T DK2004676T3 (da) 2006-03-10 2007-03-09 Peptider af regulatoriske eller accessoriske proteiner af hiv, sammensætninger og anvendelse deraf
DK11167363.8T DK2392587T3 (da) 2006-03-10 2007-03-09 Peptidsekvenser og sammensætninger

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11167363.8T DK2392587T3 (da) 2006-03-10 2007-03-09 Peptidsekvenser og sammensætninger

Country Status (20)

Country Link
US (4) US20100055119A1 (da)
EP (2) EP2392587B1 (da)
JP (3) JP2009529570A (da)
KR (1) KR20080106467A (da)
CN (2) CN102443052B (da)
AP (2) AP2015008680A0 (da)
AU (1) AU2007226430B2 (da)
BR (1) BRPI0708708A2 (da)
CA (1) CA2645342A1 (da)
DK (2) DK2004676T3 (da)
EA (1) EA019733B1 (da)
ES (2) ES2616341T3 (da)
IL (2) IL193965A0 (da)
MX (1) MX2008011520A (da)
NO (1) NO20083576L (da)
NZ (1) NZ570708A (da)
PL (1) PL2392587T3 (da)
SG (1) SG170092A1 (da)
UA (1) UA97800C2 (da)
WO (1) WO2007104932A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CN105980405A (zh) 2013-12-08 2016-09-28 派特塞尔有限公司 Hiv抗原和抗体及其组合物、方法和用途
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
DE4141970C2 (de) 1991-12-16 1998-02-19 Charite Med Fakultaet Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
DE69416824T2 (de) 1993-10-14 1999-07-08 Seikagaku Corp., Tokio/Tokyo Polypeptide und daraus hergestellte, gegen hiv wirksame substanzen
EP0728764A4 (en) 1993-10-19 1999-01-20 Ajinomoto Kk PEPTIDE THE IMMUNE RESPONSE TO HIV UNDUCED AND MEDICINAL PRODUCTS CONTAINING THE PREVENTION OR TREATMENT OF AIDS
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
WO1998052970A1 (en) * 1997-05-20 1998-11-26 St. Luke's-Roosevelt Hospital Vif-derived hiv protease inhibitors
WO1999013896A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Attenuated vif dna immunization cassettes for genetic vaccines
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
JP2002540768A (ja) * 1999-02-19 2002-12-03 ユーリッヒ シューベルト ヒト免疫不全ウイルス1型(HIV−1)ウイルス性調節タンパク質R(Vpr)の合成ペプチドおよびその適用
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
EP1225907A4 (en) * 1999-10-05 2005-06-22 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
JP2003523365A (ja) 2000-01-28 2003-08-05 スタテンズ セーラム インスティテュート Hiv感染の診断及びコントロールのためのhivペプチド及びそれをエンコードする核酸
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
AU2002211490A1 (en) * 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
JP2004535369A (ja) * 2001-03-01 2004-11-25 アメリカ合衆国 試薬およびワクチンとして使用するための免疫原性hivペプチド
RU2214274C2 (ru) 2001-08-16 2003-10-20 Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
WO2003015702A2 (en) * 2001-08-16 2003-02-27 The General Hospital Corporation Epitopes of human immunodeficiency virus-1
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
US20040001845A1 (en) 2002-05-20 2004-01-01 Marcus Altfeld Cytotoxic T-cell epitopes of HIV-1 virus
JP2006512300A (ja) 2002-10-03 2006-04-13 エピミューン インコーポレイテッド Hla結合ペプチド及びその使用
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
CA2539325C (en) * 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
EP2420248A1 (en) * 2004-08-17 2012-02-22 Institut Gustave Roussy Mutated HIV NEF for modulating immunity
US8119140B2 (en) 2005-08-23 2012-02-21 Los Alamos Security, LLC Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins

Also Published As

Publication number Publication date
PL2392587T3 (pl) 2016-08-31
EA019733B1 (ru) 2014-05-30
ES2573105T3 (es) 2016-06-06
HK1171027A1 (en) 2013-03-15
MX2008011520A (es) 2009-01-07
US20150182618A1 (en) 2015-07-02
JP6422698B2 (ja) 2018-11-14
AP3642A (en) 2016-03-16
US20170281750A1 (en) 2017-10-05
JP2009529570A (ja) 2009-08-20
AU2007226430B2 (en) 2013-08-29
KR20080106467A (ko) 2008-12-05
EP2004676A2 (en) 2008-12-24
IL193965A0 (en) 2011-08-01
NO20083576L (no) 2008-12-10
WO2007104932A2 (en) 2007-09-20
CN102443052A (zh) 2012-05-09
US20100055119A1 (en) 2010-03-04
US8992934B2 (en) 2015-03-31
SG170092A1 (en) 2011-04-29
EP2004676B1 (en) 2016-11-16
UA97800C2 (uk) 2012-03-26
CN104558126B (zh) 2020-02-14
EA200870342A1 (ru) 2009-02-27
CN104558126A (zh) 2015-04-29
EP2392587B1 (en) 2016-05-04
BRPI0708708A2 (pt) 2011-06-07
DK2392587T3 (da) 2016-05-23
US10034933B2 (en) 2018-07-31
AU2007226430A2 (en) 2008-10-09
EP2392587A1 (en) 2011-12-07
JP2015007069A (ja) 2015-01-15
AP2015008680A0 (en) 2015-08-31
US20130039937A1 (en) 2013-02-14
AU2007226430A1 (en) 2007-09-20
US9675686B2 (en) 2017-06-13
NZ570708A (en) 2011-12-22
AP2008004609A0 (en) 2008-10-31
CA2645342A1 (en) 2007-09-20
CN102443052B (zh) 2014-12-31
ES2616341T3 (es) 2017-06-12
WO2007104932A3 (en) 2007-11-22
IL219544A0 (en) 2012-06-28
JP2013040172A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
US11439702B2 (en) Influenza peptides and compositions
US10034933B2 (en) HIV and immunogenic peptide sequences and compositions
CN101400693A (zh) Hiv的调节或辅助蛋白的肽、组合物及它们的应用
AU2013201008B2 (en) Peptide sequences and compositions
HK1171027B (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof